Skip to main content

RAPT

Stock
Health Care
Biotechnology

Performance overview

RAPT Price
Price Chart

Forward-looking statistics

Beta
1.74
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Company info

SectorHealth Care
IndustryBiotechnology
Employees131
Market cap$134.0M

Fundamentals

Enterprise value-$43.2M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity2.16

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$19.84
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth-0.7
Credit+8.1
Liquidity+0.4
Inflation-5.0
Commodities-1.5
Interest Rates-3.0

Valuation

Dividend yield0.00%
PEG Ratio-4.26
Price to sales
P/E Ratio-4.26
Enterprise Value to Revenue
Price to book0.75

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?

The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research (July 15, 2025)
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know

The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research (June 18, 2025)
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

On Monday, Rapt Therapeutics, Inc. RAPT stock is trading lower after the company announced it was terminating its zelnecirnon (RPT193) program.

Benzinga (November 11, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free